New study aims to find best CMV prevention for kidney transplant patients
NCT ID NCT07430683
First seen Feb 24, 2026 · Last updated May 12, 2026 · Updated 16 times
Summary
This study looks at two different approaches to prevent cytomegalovirus (CMV) infection in people who have received a kidney transplant from a living donor and are at intermediate risk for CMV. One group gets a preventive drug (valganciclovir) for a set time, while the other group is monitored closely and treated only if the virus appears. The goal is to see which method works better to keep patients healthy after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universidad de Guadalajara
Guadalajara, Jalisco, 44280, Mexico
Conditions
Explore the condition pages connected to this study.